<DOC>
	<DOCNO>NCT00540072</DOCNO>
	<brief_summary>A COMPARASON OF CIDECIN™ ( DAPTOMYCIN ) TO ROCEPHIN® ( CEFTRIAXONE ) IN THE TREATMENT OF MODERATE TO SEVERE COMMUNITY-ACQUIRED ACUTE BACTERIAL PNEUMONIA DUE TO S. PNEUMONIAE</brief_summary>
	<brief_title>Study Cidecin™ ( Daptomycin ) Rocephin® ( Ceftriaxone ) Treatment Moderate Severe Community-Acquired Acute Bacterial Pneumonia Due S. Pneumoniae</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>1 . Provide sign date informed consent . 2 . Adults , 18 year age old either gender race weigh 150 kg . Female patient childbearing potential MUST nonpregnant ( confirm negative serum pregnancy test ) , nonlactating , must willing practice reliable birth control measure least 30 day treatment study drug ( ) . 3 . Have new pulmonary infiltrate chest radiograph . 4 . Exhibit least two follow clinical symptom pneumonia history physical : Cough Production purulent sputum change character sputum Auscultatory finding pulmonary examination rale and/or evidence pulmonary consolidation ( dullness percussion , bronchial breath sound , egophony ) Dyspnea tachypnea Documented fever , define body temperature &gt; 38.0 ºC ( 100.4 ºF ) take orally ; &gt; 38.5 ºC ( 101.2 ºF ) tympanically ; &gt; 39.0 ºC ( 102.2 ºF ) rectally hypothermia , define core body temperature &lt; 35.0 ºC ( 95.0 ºF ) An elevated total peripheral white blood cell count ( WBC &gt; 10,000/mm3 ) ; &gt; 15 % immature neutrophil ( band ) , regardless total peripheral white count ; leukopenia total WBC &lt; 4500/mm3 . Hypoxemia PO2 &lt; 60 mmHg ( room air ) O2 saturation &lt; 90 % room air 5 . Pneumonia require hospitalization intravenous therapy least 5 day . 6 . Willingness participate study complete followup assessment . 1 . Patients Grade V pneumonia ( base Fine Score ; Attachment 8 ) . 2 . Patients respiratory failure incipient respiratory failure patient candidate mechanical ventilation ( reason ) . 3 . Any following pulmonary condition may preclude interpretation study result : Cystic fibrosis Primary lung cancer another malignancy metastatic lung Known bronchial obstruction history postobstructive pneumonia Known suspect active tuberculosis . 4 . Severe shock ( systolic blood pressure &lt; 90 mm Hg &gt; 30 minute correct fluid bolus ) . 5 . Clinical evidence bacterial meningitis ( base lumbar puncture result ) . 6 . Severe renal impairment ( calculated creatinine clearance &lt; 30 mL/min ) . 7 . Moribund clinical condition : high likelihood death first 48 hour . 8 . If HIV positive , know CD4 count &lt; 200/mm3 evidence Pneumocystis carinii pneumonia . 9 . Inability tolerate ceftriaxone history allergy betalactam antibiotic ( history rash alone exclude patient ) . 10 . Any individual previously treat potentially effective antiinfective agent &gt; 24 hour ( one dose day ) within 72 hour enrollment , prior treatment investigational drug ( include experimental biologic agent ) previous 30 day prior therapy daptomycin . 11 . Patients must continue HMGCoA reductase inhibitor therapy ( e.g. , simvastatin , lovastatin , etc . ) study treatment period . 12 . Anticipation second nonprotocol systemic antibiotic require . 13 . Induction chemotherapy within 2 week prior enrollment ( exogenous therapy anticipate result PMN count &lt; 200 mm3 Treatment Phase ) , patient severe neutropenia ( &lt; 200 PMN cells/mm3 ) . 14 . Patients consider unreliable return visit comply study procedure . 15 . Progressive neoplastic disease ( Note : patient malignancy remission eligible ) . 16 . Women pregnant nursing/lactating . 17 . Patients present nosocomial pneumonia ( i.e. , &lt; 14 day discharge skilled nursing facility hospital initial hospitalization &gt; =3 day duration ) . 18 . Clinical suspicion Legionella pneumonia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Moderate Severe Community-Acquired Acute Bacterial Pneumonia Due S. Pneumoniae</keyword>
</DOC>